PRISM MediaWire

PRISM MarketView

Incannex’s Psilocybin Targets Anxiety with Positive Topline Results

New York, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView - Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved positive topline results in its Phase 2 clinical trial of psilocybin in generali...

29 February 2024

PRISM MarketView

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

NEW YORK, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million ...

29 February 2024

PRISM MarketView

Investors Are Having a Cow. Plant-Based Beyond Meat (BYND) Exceeds Q4 Revenue Estimates, Promises to Steeply Cut Costs.

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - PRISM Zombie Index Leader Beyond Meat, Inc. (BYND), is seeing a big gain today as its trading close to 45% higher on its recent earnings release. However, outside of exceeding the Street’s Q4 revenu...

28 February 2024

brooqLy, Inc. enters into an Agreement with CIM Securities to raise up to $3,000,000 in Funding

Palos Hills, IL, February 28, 2024 - PRISM MediaWire - brooqLy, Inc (OTC: BRQL), an innovative technology company, reported today that it has entered into an engagement agreement with CIM Securities, LLC, a FINRA member broker-dealer as the Managing Placement Agent to ra...

28 February 2024

PRISM MarketView

MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with positive Phase 2b results for MM120 ...

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Rare disease company, Capricor Therapeutics (Nasdaq: CAPR), has been granted an in-person Type-B meeting with the FDA to discuss chemistry, manufacturing and controls (CMC) plans for commercial laun...

28 February 2024

SPZI: JP 3E Holdings, Inc. Receives $23 Million, Purchasing Kokomo, Indiana Harmony Villas Project & Adds Rocky H. Singh to its Team

JP 3E Holdings, Inc., formerly Spooz Inc., receives $18,000,000 from the city of Kokomo, IN and the state of Indiana to fund the Harmony Villas Project. Rocky H. Singh, as a newly added Director, will manage the Harmony Villas Project and will add an additional $5,000,00...

28 February 2024

EP3Oil ENTERS INTO AN LOI FOR DRILLING ON THE WINDY POINTE OIL RESERVE IN TEXAS

Holiday Island, Ark., February 28, 2024 - PRISM MediaWire - Holiday Island Holdings, Inc. - soon to be EP3Oil, Inc.- (OTC: HIHI) has a deal for a 40-acre lease and development of Windy Pointe in central Texas.

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Voyager Therapeutics Selects Development Candidate for Friedreich’s Ataxia, Triggers $5M Milestone Payment

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Voyager Therapeutics (Nasdaq: VYGR) has selected a lead development candidate in its Friedreich’s Ataxia (FA) program. The company expects the program to advance into first-in-human clinical trials ...

27 February 2024

PRISM MarketView

AdTech and Media PRISM Index Leader PubMatic, Inc. Rises 27% On Earnings Beat

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Digital advertising tech company PubMatic, Inc. (PUBM) has rose ~27% after announcing record earnings after the market closed on Monday. The stock is currently trading around $21/share with 1.7M sha...

27 February 2024